VIRI Virios: Earnings per share for the trailing year

Official company branding of Virios Therapeutics Inc. (VIRI)

Virios Therapeutics (VIRI) is mitigating pipeline risks by adapting antiviral agents for various diagnoses. This daily price chart of the EPS TTM metric provided by GURU.Markets confirms a trend where 81.40 represents the current level of the indicator. Development is being conducted through scientific alliances in pain therapy, while future profitability relies exclusively on the patent protection of the drugs.

VIRI Virios Therapeutics Inc. Earnings per share for the last twelve months (02/11/2024 - 02/20/2024)

Virios Therapeutics Inc. - analytical breakdowns and key metrics (VIRI)

- market price and analyst price targets:
Initial company analysis:Virios Therapeutics Inc. VIRI
Flagship merchandise of Virios Therapeutics, Inc.

The development of antiviral drugs by Virios Therapeutics (VIRI) depends directly on clinical trial outcomes and patent protection. These factors determine financial stability, which is immediately reflected in the earnings per share (EPS) dynamics. This metric measures the annual rate of change in net income over the last 12 months, neutralizing quarterly volatility. The smoothed curve allows for an objective assessment of the business development's analytical momentum. The current YoY TTM growth in net income per share serves as an indicator of the balance between supply and demand.

Competitor analysis for Virios Therapeutics

Net earnings per share for the last four quarters Gilead GILD|Cidara Corp (CDTX) - Earnings per share for the last twelve months|Novavax, Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months CVAC|Net earnings per share (EPS TTM) valneva.com|Net earnings per share for the last 12 months VIR (Vir Biotechnology)|Net earnings per share for the last four quarters SIGA Technologies Inc|Earnings per share for the last twelve months Emergent Bio EBS|Net earnings per share (EPS TTM) Atea Pharmaceuticals AVIR|IVVD - Earnings per share for the last twelve months|ENTA (Enanta Pharmaceuticals) - Earnings per share for the last 12 months|INO (Inovio) - Net earnings per share for the last 12 months|HLVX (HilleVax Inc) - Earnings per share for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months DYAI (Dyadic International)|Net earnings per share for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Earnings per share for the trailing year|Earnings per share for the last twelve months Cocrystal Pharma Inc COCP|Earnings per share for the trailing year TRAW|Dogwood Therapeutics Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months VBI Vaccines, Inc.|Earnings per share for the last twelve months Vaxart